Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia…
By Peter B. Jones, T. Barnes, L. Davies, G. Dunn, H. Lloyd, K. Hayhurst, Robin M. Murray, A. Markwick, Shôn Lewis. Archives of General Psychiatry, 2006
1,057 citations recorded by the source corpus.
Subfields: Clinical Psychology, Geriatrics and Gerontology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/e542126fd323d413e1db0e4dfab89c969defa195
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Psychiatry and Mental health
Citations in the corpus
- Cognitive Behavior Therapy for Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor (2007, neutral): “High CTAM 0.147 � 0.172, 0.466 8.49 (4), not significant 5 347 � 0.058, 0.782 Low CTAM 0.509 0.221, 0.797 23.04 ( 9 ), significant at the 5% level 10 520”
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, methodology): “For the treatment of secondary negative symptoms, both FGAs and SGAs have a modest effi cacy.”